期刊文献+

亚胺培南耐药鲍曼不动杆菌耐药基因分析 被引量:2

Drug resistance gene analysis on imipenem-resistant Acinetobacter baumannii
原文传递
导出
摘要 目的了解淮南朝阳医院亚胺培南耐药鲍曼不动杆菌(Acinetobacter baumannii,Ab)耐药基因表型,为指导临床合理用药和院内感染的防控提供依据。方法收集2020年1—12月淮南朝阳医院分离的20株亚胺培南耐药鲍曼不动杆菌,对菌株药敏试验结果进行分析,采用聚合酶链式反应(polymerase chain reaction,PCR)检测各株细菌耐碳青霉烯类基因携带情况。结果20株鲍曼不动杆菌均为呼吸道标本;神经外科11株(55%),重症监护病房(ICU)6株(30%),呼吸科2株(10%),肝胆外科1株(5%)。20株亚胺培南耐药鲍曼不动杆菌除对复方新诺明耐药率较低外,对其它抗生素耐药率均较高。PCR检测20株鲍曼不动杆菌OXA-51和OXA-23均为阳性,OXA-24、VIM-1、VIM-2、IPM-1、NDM-1均未检出。结论淮南朝阳医院亚胺培南耐药鲍曼不动杆菌耐药形势比较严峻,耐药机制可能与OXA-51和OXA-23耐药基因有关。医护人员应当引起重视,医院感染管理科应采取相应措施,避免耐药菌株扩散。 Objective To provide the basis for rational clinical medication and prevention and control of nosocomial infection by understanding the drug resistance gene phenotype of imipenem-resistant Acinetobacter baumannii(Ab)in Huainan Chaoyang Hospital.Methods Twenty strains of imipenem-resistant Acinetobacter baumannii isolated in Huainan Chaoyang Hospital from January to December 2020 were collected,the results of the bacterial susceptibility test was analyze,and polymerase chain reaction(PCR)was used to detect the carrying status of bacterial resistance of carbapenem genes of strains.Results All the 20 strains of Acinetobacter baumannii were respiratory specimens;there were 11 strains for the neurosurgery department(55%),6 strains for intensive care unit(ICU)(30%),2 strains for the respiratory department(10%),and 1 strain in hepatobiliary surgery(5%).The low resistance rate of 20 strains of Acinetobacter baumannii resistant to imipenem against other antibiotics was higher except that against compound trimethoprim.All 20 strains of Acinetobacter baumannii OXA-51 and OXA-23 tested to be positive under the PCR,and neither OXA-24 nor VIM-1 or VIM-2 or IPM-1 or NDM-1 was detected.Conclusion The drug resistance of imipenem-resistant Acinetobacter baumannii in Huainan Chaoyang Hospital is relatively severe,and the resistance mechanism may be related to the resistance genes of OXA-51 and OXA-23.Medical workers should pay close attentions to the problems,and the nosocomial infection control department should take appropriate measures to avoid the spread of drug-resistant strains.
作者 孙启山 湛孝东 唐小牛 姜玉新 SUN Qi-shan;ZHAN Xiao-dong;TANG Xiao-niu;JIANG Yu-xin(Huainan Chaoyang Hospital,Anhui232001,China)
出处 《医学动物防制》 2022年第4期354-356,共3页 Journal of Medical Pest Control
基金 国家自然科学基金(81671586) 安徽高校省级自然科学研究项目(KJ2018A0263)。
关键词 鲍曼不动杆菌 耐药机制 亚胺培南 碳青霉烯酶 Β-内酰胺酶 耐药性 分析 基因 Acinetobacter baumannii Drug resistance mechanism Imipenem Carbapenemases β-lactamases Drug resistance Analysis Gene
  • 相关文献

参考文献7

二级参考文献60

  • 1Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen[J]. Pathog Dis, 2014,71 (3) :292-301.
  • 2Chaari A, Mnif B, Bahloul M, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors[J]. Int J Infect Dis, 2013, 17(12): e1225 e1228.
  • 3Decousser JW, Jansen C, Nordmann P, et al. Outbreak of NDM-l-producing Acinetobacter baumannii in France, January to May 2013. [J]. Euro Surveill, 2013, 18(31):pii: 20547.
  • 4Scott P, Deye G, Srinivasan A, et al. An outbreak of multidrug-resistant Acinetobacter baurr:nnii caleoaeeticus complex infection in the US military health care system associated with military operations in lraq[J]. Clin Infect Dis, 2007, 44(12) : 1577-1584.
  • 5Seiffert SN, Hilty M, Perreten V, et al. Extended spectrum cephalosporimresist ant Gram negative organisms in livestock: an emerging problem for human health? [J]. Drug Resist Update, 2013, 16(1 2): 22 45.
  • 6Girlich D, Poirel L, Nordmann P. First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate [ J ]. Antimicrob Agents Chemother, 2010, 54(1): 578-579.
  • 7Peleg AY, Seifert H, Paterson DL. Acinetobacter baurnannii: emergence of a successful pathogen[J]. Clin Miriobiol Rev, 2008, 21(3) : 538-582.
  • 8Abbott I, Cerqueira GM, Bhuiyan S, et al. Carbapenem resistance in Acinetobacterbaumannii : laboratory challenges, mechanistic insights and therapeutic strategies [J]. Expert Rev Anti Infect Ther, 2013, 11 (4) : 395 409.
  • 9Spapen H, Jacobs R, Van Gorp V, et al. Renal and neurological side effects of colistin in critically ill patients[J]. Ann Intensive Care, 2011, 1(1) :14.
  • 10Cai Y, Wang R. Tigeeycline: benifits and risks[J]. Lancet Infect Dis, 2011, 11 (11 ) : 804-805.

共引文献1145

同被引文献28

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部